GOODWILL AND OTHER INTANGIBLE ASSETS

12 Months Ended

Oct. 31, 2019

Goodwill and Intangible Assets Disclosure [Abstract]

The following table presents goodwill balances and the movements for each of our reportable segments during the years ended October 31, 2018 and 2019:



	Life Sciences and Applied Markets			Diagnostics and Genomics			Agilent CrossLab			Total
	(in millions)
Goodwill as of October 31, 2017	$	773		$	1,330		$	504		$	2,607
Foreign currency translation impact	(7		)	(4		)	(4		)	(15		)
Goodwill arising from acquisitions	37			281			63			381
Goodwill as of October 31, 2018	$	803		$	1,607		$	563		$	2,973
Foreign currency translation impact	(1		)	(2		)	(2		)	(5		)
Goodwill arising from acquisitions and adjustments	636			(11		)	—			625
Goodwill as of October 31, 2019	$	1,438		$	1,594		$	561		$	3,593

As of September 30, 2019, our annual impairment test date, we assessed goodwill impairment for our reporting units and no impairment was indicated.

The component parts of other intangible assets at October 31, 2018 and 2019 are shown in the table below:



	Other Intangible Assets
	Gross Carrying Amount		Accumulated Amortization and Impairments		Net Book Value
	(in millions)
As of October 31, 2018:
Purchased technology	$	947	$	683	$	264
Trademark/Tradename	151		88		63
Customer relationships	107		63		44
Third-party technology and licenses	$	28	$	19	$	9
Total amortizable intangible assets	$	1,233	$	853	$	380
In-Process R&D	111		—		111
Total	$	1,344	$	853	$	491
As of October 31, 2019:
Purchased technology	$	1,413	$	763	$	650
Backlog	5		5		—
Trademark/Tradename	196		102		94
Customer relationships	329		87		242
Third-party technology and licenses	$	28	$	22	$	6
Total amortizable intangible assets	$	1,971	$	979	$	992
In-Process R&D	115		—		115
Total	$	2,086	$	979	$	1,107

In 2019, we acquired two businesses, BioTek and ACEA, for a combined purchase price of approximately $1.4 billion. See Note 3, "Acquisitions", for additional information.

During fiscal year 2019, we recorded additions to goodwill of $636 million and to other intangible assets of $744 million related to the acquisition of ACEA and BioTek. In the second quarter of fiscal year 2019, we recorded a measurement period adjustment to goodwill of $11 million for deferred tax assets related to pre-acquisition net operating losses of Advanced Analytical Technologies, Inc. The increase to other intangible assets due to foreign currency translation was not material in 2019.

During fiscal year 2018, we recorded additions to goodwill of $381 million and to intangible assets of $262 million related to the acquisition of seven businesses. During the year other intangible assets decreased $1 million, due to the impact of foreign exchange translation.

In general, for United States federal tax purposes, goodwill from asset purchases is amortizable however any goodwill created as part of a stock acquisition is not deductible.

In 2019, there were no impairments of other intangible assets recorded. During 2018, we recorded an impairment charge of $21 million related to purchased intangible assets within the diagnostics and genomics segment that were deemed unrecoverable. In 2017, there were no impairments of other intangible assets recorded.

Amortization expense of intangible assets was $128 million in 2019, $110 million in 2018, and $120 million in 2017.

Future amortization expense related to existing finite-lived purchased intangible assets associated with business combinations for the next five fiscal years and thereafter is estimated below:



Estimated future amortization expense:
	(in millions)
2020	$	186
2021	$	172
2022	$	150
2023	$	107
2024	$	86
Thereafter	$	291